Opinion

In Re Orthopedic Bone Screw Products Liability Litigation

  • 193 F.3d 781
Court
Court of Appeals for the Third Circuit
Filed
Oct 7, 1999
Author
Scirica
On the bench
Scirica, Roth, McKay
Cited by
1 cases
Authority
More cited than 52.6%

The opinion

Opinions of the United

1999 Decisions States Court of Appeals

for the Third Circuit

10-7-1999

In Re Orthopedic Bone Screw Litigation

Precedential or Non-Precedential:

Docket 98-1762, 98-1829

Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_1999

Recommended Citation

"In Re Orthopedic Bone Screw Litigation" (1999). 1999 Decisions. Paper 279.

http://digitalcommons.law.villanova.edu/thirdcircuit_1999/279

This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova

University School of Law Digital Repository. It has been accepted for inclusion in 1999 Decisions by an authorized administrator of Villanova

University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu.

Filed October 7, 1999

UNITED STATES COURT OF APPEALS

FOR THE THIRD CIRCUIT

Nos. 98-1762 & 98-1829

IN RE: ORTHOPEDIC BONE SCREW PRODUCTS

LIABILITY LITIGATION

Plaintiffs Legal Committee,

Appellant at 98-1762

American Academy of Orthopaedic Surgeons,

North American Spine Society, and Scoliosis

Research Society (the Medical Associations),

Appellants at 98-1829

On Appeal from the United States District Court

for the Eastern District of Pennsylvania

MDL No. 1014

(Honorable Louis C. Bechtle)

Argued April 26, 1999

Before: SCIRICA, ROTH and McKAY,* Circuit Judges

(Filed October 7, 1999)

_________________________________________________________________

*The Honorable Monroe G. McKay, United States Circuit Judge for the

Tenth Judicial Circuit, sitting by designation.

MICHAEL D. FISHBEIN, ESQUIRE

(ARGUED)

ARNOLD LEVIN, ESQUIRE

SANDRA L. DUGGAN, ESQUIRE

Levin, Fishbein, Sedran & Berman

510 Walnut Street, Suite 500

Philadelphia, Pennsylvania 19106

Attorneys for Plaintiffs

Legal Committee,

Appellant at 98-1762/

Cross-Appellee at 98-1829

FREDERICK KRUTZ, ESQUIRE

(ARGUED)

Forman, Perry, Watkins, Krutz

& Tardy

188 East Capitol Street

One Jackson Place, Suite 1200

Jackson, Mississippi 39225-2608

Attorney for American Academy of

Orthopaedic Surgeons, North

American Spine Society, and

Scoliosis Research Society,

Appellees at 98-1762/

Cross-Appellants at 98-1829

MITCHELL A. STEARN, ESQUIRE

Porter, Wright, Morris & Arthur

1667 K Street, N.W., Suite 1100

Washington, D.C. 20006

NORMAN J. JEDDELOH, ESQUIRE

Arnstein & Lehr

120 South Riverside Plaza,

Suite 1200

Chicago, Illinois 60606

Attorneys for American Academy of

Orthopaedic Surgeons,

Appellee at 98-1762/

Cross-Appellant at 98-1829

2

DANIEL J. MULHOLLAND, ESQUIRE

Forman, Perry, Watkins, Krutz

& Tardy

188 East Capitol Street

One Jackson Place, Suite 1200

Jackson, Mississippi 39225-2608

SHAWN M. COLLINS, ESQUIRE

The Collins Law Firm

1979 North Mill Street, Suite 109

Naperville, Illinois 60563

Attorneys for North American

Spine Society,

Appellee at 98-1762/

Cross-Appellant at 98-1829

JANET L. MacDONELL, ESQUIRE

Deutsch, Kerrigan & Stiles

755 Magazine Street

New Orleans, Louisiana 70130

Attorney for Scoliosis Research

Society,

Appellee at 98-1762/

Cross-Appellant at 98-1829

THOMAS G. STAYTON, ESQUIRE

Baker & Daniels

300 North Meridian Street,

Suite 2700

Indianapolis, Indiana 46204

ALBERT J. DAHM, ESQUIRE

Baker & Daniels

111 East Wayne Street, Suite 800

Fort Wayne, Indiana 46802

Attorneys for Zimmer, Inc.,

Appellee at 98-1829

3

MICHAEL R. FRUEHWALD,

ESQUIRE

Barnes & Thornburg

11 South Meridian Street,

Suite 1313

Indianapolis, Indiana 46204

Attorney for Ace Medical Company

and DePuy Motech, Inc.,

Appellees at 98-1762

J. KURT STRAUB, ESQUIRE

Obermayer, Rebmann, Maxwell

& Hippel

1617 John F. Kennedy Boulevard

One Penn Center, 19th Floor

Philadelphia, Pennsylvania 19103

Attorney for Scientific Spinal, Ltd.,

Appellee at 98-1762

ROBERT R. REEDER, ESQUIRE

Cozen & O'Connor

The Atrium

1900 Market Street

Philadelphia, Pennsylvania 19103

Attorney for Synthes, Inc.,

Synthes (USA), and Synthes North

America, Inc.,

Appellees at 98-1762/1829

4

PHILIP H. LEBOWITZ, ESQUIRE

(ARGUED)

Pepper, Hamilton & Scheetz

18th & Arch Streets

3000 Two Logan Square

Philadelphia, Pennsylvania

19103-2799

Attorney for Danek Medical, Inc.,

Sofamor, S.N.C., Sofamor Danek

Group, Inc., Warsaw Orthopedic,

Inc., Sofamor, Inc., Texas Scottish

Rite Hospital for Children,

Eduardo Luque, M.D., Charles E.

Johnston, II, M.D., Richard

Ashman, Ph.D., Gary Lowery,

M.D., George S. Rapp, M.D., Ensor

Transfeldt, M.D., John A. Herring,

M.D., Thomas Whitecloud, III,

M.D., Thomas Zdeblick, M.D.,

Appellees at 98-1762

RAYMOND J. PAJARES, ESQUIRE

Aubert & Pajares

3850 North Causeway Boulevard

Two Lakeway Center, Suite 1650

Metarie, Louisiana 70002

Attorney for Advanced Spine

Fixation System, Inc.,

Appellee at 98-1762

SUSAN S. WETTLE, ESQUIRE

DOUGLAS W. LANGDON, ESQUIRE

Brown, Todd & Heyburn

400 West Market Street, Suite 3200

Louisville, Kentucky 40202

Attorneys for Youngwood Medical

Specialties, Inc., f/k/a National

Medical Speciality, Inc., f/k/a

Stuart Medical Specialty, Inc.;

Stuart Medical, Inc., f/k/a Stuart

Drug and Surgical Supply, Inc.,

Appellees at 98-1762/1829

5

JAMES B. IRWIN, ESQUIRE

NATHAN T. GISCLAIR, ESQUIRE

Montgomery, Barnett, Brown, Read,

Hammond & Mintz

1100 Poydras Street

3200 Energy Centre

New Orleans, Louisiana 70163-3200

Attorneys for Smith & Nephew,

Inc.,

Appellee at 98-1762/1829

BRENDA N. HIGHT, ESQUIRE

McManemin & Smith

600 North Pearl Street, Suite 1600

Dallas, Texas 75201

Attorney for Estate of

David K. Selby,

Appellee at 98-1762/1829

CAROLINE P. GOLDEN, ESQUIRE

JOHN N. SCHOLNICK, ESQUIRE

BRADLEY C. TWEDT, ESQUIRE

Neal, Gerber & Eisenberg

Two North LaSalle Street,

Suite 2300

Chicago, Illinois 60602

Attorneys for GICD/USA Institute,

Inc.,

Appellee at 98-1762/1829

OPINION OF THE COURT

SCIRICA, Circuit Judge.

This is an appeal of the District Court's dismissal under

Fed. R. Civ. P. 12(b)(6) of conspiracy and concert of action

claims alleged by thousands of plaintiffs in multidistrict

litigation involving allegedly defective bone screw

implantation devices. The District Court held the claims,

insofar as they alleged a conspiracy to violate the Federal

Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C.A. S 301-

397 (West Supp. 1999), did not state a cause of action

6

upon which relief can be granted. Accordingly, the court

granted defendants' motions to dismiss those claims.

The District Court also made several rulings unfavorable

to the defendants. The court denied with prejudice their

motions to dismiss based on improper pleading and First

Amendment protection. Additionally, the District Court

denied the motions of several defendants for attorney's fees,

costs, and sanctions. These rulings are now challenged on

cross-appeal.

We will affirm the judgment of the District Court on all

issues.

I. BACKGROUND

This multidistrict litigation comprises more than 2,000

civil actions originally filed in approximately sixty of the

ninety-four federal districts. In August 1994, the cases were

consolidated in the Eastern District of Pennsylvania under

28 U.S.C. S 1407. All of the approximately 5,000 individual

plaintiffs claim to have suffered physical injuries caused by

defective orthopedic bone screw devices affixed to the

pedicles of their spines during spinal fusion surgery. The

devices, which are intended to stabilize the spine and

achieve fusion of the vertebrae, consist of rods or plates

that are screwed into the vertical axis of the lumbar spine.

In most cases, plaintiffs allege the devices broke after being

implanted in their spines. In some instances, plaintiffs have

undergone surgery to have the devices removed; in others,

the broken devices could not be removed.

Plaintiffs' original claims, filed in early 1994, set forth

causes of action based on both federal statutes and state

law tort and contract principles. Generally, they named as

defendants only the manufacturers and distributors of the

bone screw devices. Subsequent actions named a broader

array of defendants and stated additional theories of

recovery. In particular, hundreds of so-called "omni"

actions, first brought in October 1995, name as defendants

the manufacturers, designers, and distributors of the

devices; trade associations that conducted seminars on

their use; regulatory consultants; and physicians who

promoted the product. There are two types of omni actions.

7

The Plaintiffs' Legal Committee ("PLC") actions allege both a

horizontal conspiracy involving manufacturers and a

vertical conspiracy involving all of the defendants. The

Lestelle actions (so named after the attorney who drafted

the form complaint that served as the basis of these

actions) allege only a horizontal conspiracy involving

manufacturers. In addition to the conspiracy and concert of

action claims, the omni complaints allege fraud; negligent

misrepresentation; strict liability in tort; liability per se;

negligence; breach of implied warranty of merchantibility;

and (in some cases) loss of consortium.

In August 1996, the District Court dismissed the PLC

omni complaints in their entirety because the complaints

failed to demonstrate subject matter jurisdiction. See In re

Orthopedic Bone Screw Prods. Liability Litig., MDL No. 1014,

1996 WL 482977 (E.D. Pa. Aug. 22, 1996) (Pretrial Order

No. 477). The court also dismissed the conspiracy claims in

both the PLC and the Lestelle complaints for failure to state

a claim upon which relief could be granted, and it

dismissed the fraud claims in the Lestelle complaints

because the circumstances of fraud were not averred with

sufficient particularity. See id. All of these dismissals were

without prejudice. Plaintiffs subsequently filed hundreds of

amended omni complaints, which are the subject of this

appeal.1

Twice before, we have issued decisions in this litigation.

First, we denied the petitions of some defendants for a writ

of mandamus invalidating the District Court's dismissal of

the conspiracy and concert of action claims. See In re

Orthopedic Bone Screw Prods. Liability Litig., No. 97-1426,

1427, 1438, 1450, 1453, 1465, mem. op. (3d Cir. Nov. 10,

1997) (unpublished opinion). There we considered two of

the arguments raised by defendants here: their claim that

the First Amendment prohibits imposition of liability for

their speech at the seminars, and their contention that the

omni complaints fail to plead reliance and causation

adequately. Although these arguments did not persuade us

to grant the "extraordinary remedy" of mandamus relief, In

_________________________________________________________________

1. For ease of reference, we will refer to the amended omni complaints

simply as the "omni complaints."

8

re Asbestos Sch. Litig. (Pfizer Inc.), 46 F.3d 1284, 1288 (3d

Cir. 1994), we noted that the standards governing a

mandamus petition are more stringent than those

governing a direct appeal, and that our disposition did not

preclude defendants from asserting their arguments at a

later stage in the proceedings. Accordingly, our denial of a

writ of mandamus has no binding effect in the present

appeal. More recently, we determined that plaintiffs' state

law claims of fraud on the FDA were not preempted by the

Medical Device Amendments of 1976, 21 U.S.C.A. SS 360c-

360k (West Supp. 1999) ("MDA"). See In re Orthopedic Bone

Screw Prods. Liability Litig., 159 F.3d 817 (3d Cir. 1998).

A. Regulatory Framework

The conspiracy and concert of action claims at issue here

require some discussion of the regulatory framework

governing orthopedic bone screw devices. It is undisputed

that the devices are regulated by the FDCA, as amended by

the MDA. At the time the lawsuits were filed, the FDA had

classified the bone screw devices as "Class III" devices

because they "present a potential unreasonable risk of

illness or injury." 21 U.S.C. S 360c(a)(1)(C)(ii)(II).

Consequently, one must receive "premarket approval"

before commercially distributing or selling them. Id.

S 360e(a). To obtain the data to support an application for

premarket approval, a manufacturer may use the device in

clinical trials under active FDA supervision pursuant to the

FDCA's Investigational Device Exemption ("IDE") provisions

and accompanying federal regulations. Id. S 360j(g); 21

C.F.R. pt. 812 (1998). Premarket approval will be granted

only if the IDE investigation proves the device is sufficiently

safe and effective.

Premarket approval is not required if the FDA determines

the device is "substantially equivalent" to a legally marketed

"predicate device" (that is, a device marketed before the

Medical Device Amendments went into effect on May 28,

1976) in terms of its intended use, technological

characteristics, safety, and effectiveness. 21 U.S.C.

S 360e(b)(1)(B); 21 C.F.R. S 807.100(b). A determination of

substantial equivalence is called "510(k) clearance" in

reference to the applicable section of the original Act. If a

device obtains 510(k) clearance, it may be introduced into

9

commerce without premarket approval. Alternatively, the

FDA may issue an order declaring the device "not

substantially equivalent" ("NSE"), which means that it

cannot be marketed without premarket approval.

Thus, a person who wishes to market or sell a Class III

device has two primary avenues of obtaining FDA approval:

premarket approval, based on safety and efficacy data from

non-clinical laboratory studies or IDE investigation; or

510(k) clearance, based on a showing that the device is

substantially equivalent to one that was in commerce prior

to May 28, 1976.2 If a Class III medical device is introduced

into commerce without one of these two approvals, it is

deemed "adulterated" and the person who introduced the

device into commerce is criminally liable. See 21 U.S.C.

S 331(a). Similarly, it is a crime to introduce into commerce

a Class III device that is "misbranded," meaning that it does

not bear adequate directions for its intended use. See id.

B. The Omni Complaints

According to the omni complaints, in 1984 AcroMed

Corporation -- and shortly thereafter, Sofamor, Inc. and

other sellers and manufacturers -- sought 510(k) clearance

to market pedicle screw devices. The FDA denied 510(k)

clearance but approved a series of IDE clinical trials

between 1986 and 1993. Because the trials failed to

generate sufficient safety data, the FDA denied premarket

approval after each one. Allegedly, defendants then

conspired to market their bone screw devices without the

necessary FDA approvals.

The omni complaints allege two distinct conspiracies. The

first is entitled, variously, the "Sofamor Conspiracy," the

"ASFSI Conspiracy," or the "Danek Conspiracy," depending

on the particular manufacturer being sued. It is alleged

that the manufacturer entered into written agreements with

spinal surgeons and other health care professionals in

which the manufacturer agreed to provide them royalties

_________________________________________________________________

2. Premarket approval is also not required upon a showing that the

device in question was itself introduced into interstate commerce for

commercial distribution before May 28, 1976. See 21 U.S.C.

S 360e(b)(1)(A).

10

and stock options in exchange for their participation in

"seminars" instructing physicians how to use the

manufacturer's bone screw device. According to the

complaints, although the seminars were conducted in the

guise of educating fellow members of the medical

profession, they were actually akin to "Tupperware parties"

in that their true purpose was purely commercial. Plaintiffs

also claim that the physicians who conducted the seminars

did not disclose to attendees that the bone screw device

had not received FDA premarket approval or 510(k)

clearance for use in pedicle fixation surgery; that clinical

trials had actually raised serious questions about its safety

and efficacy; and that they, the physicians, had a direct

financial stake in the sale of the device.

The complaints also describe an "Intercompany/

Association Conspiracy." Under this theory, plaintiffs claim

that manufacturers of the bone screw devices paid various

professional associations to sponsor and conduct seminars

for orthopedic surgeons. The purpose of the seminars,

again, was to promote the use of orthopedic bone screws in

surgery. At the seminars, the Intercompany/Association

conspirators allegedly concealed the same basic facts as in

the first conspiracy: namely, that the FDA had not

approved the use of the devices in pedicle fixation surgery;

that studies had raised serious doubts about the safety of

using the devices in such a procedure; and that the

associations were being paid by the manufacturers to

promote the devices. Later, the Intercompany/Association

conspirators allegedly implemented a two-part scheme to

avoid civil and criminal liability for these activities. First,

they established a trade association known as the"Spinal

Implant Manufacturers Group" to conduct a retrospective

study (the "Cohort Study") of pedicle screwfixation. The

results of the Cohort Study were reported to the FDA and

published in Spine magazine in October 1994, allegedly to

achieve reclassification of the bone screw device as a Class

I or II device (obviating the need for premarket approval)

and to serve as a defense in potential criminal or civil

litigation.3 According to plaintiffs, the Cohort study was an

_________________________________________________________________

3. In July 1998, the FDA reclassified most pedicle screw fixation devices

as Class II devices. See Orthopedic Devices: Classification and

Reclassification of Pedicle Screw Spinal Systems, 63 Fed. Reg. 40,025

(1998) (codified at 21 C.F.R. S 888.3070).

11

intentional fraud, relying on selective data and ignoring

unfavorable results. Second, defendants Danek and

AcroMed allegedly agreed to mislead the FDA into believing

Zimmer4 had marketed a bone screw device for pedicle

fixation surgery in the United States before 1976, in an

attempt to obtain 510(K) clearance on the ground that the

bone screw device was "substantially equivalent" to a

predicate device.

C. District Court Proceedings

The District Court determined that although the two

conspiracies outlined in the omni complaints differ in some

respects, both essentially allege that defendants agreed to a

scheme to market and sell bone screw devices without the

necessary FDA approvals. See In re Orthopedic Bone Screw

Prods. Liability Litig., MDL No. 1014, Pretrial Order No. 861,

mem. op. at 18 (E.D. Pa. Apr. 16, 1997) [hereinafter "PTO

861"] (noting that each conspiracy "had the same single

objective: to promote and sell pedicle screw fixation devices

in violation of the FDCA").5 The court held the claims failed

to state a cause of action upon which relief could be

granted, see id. at 27, because civil conspiracy and concert

of action claims require an independent basis of tort

liability, which the FDCA does not provide. In accordance

with this ruling, the Judicial Panel for Multidistrict

Litigation began to remand all actions containing a claim of

conspiracy to violate the FDCA to transferor courts for

summary judgment proceedings and trial. Numerous

transferor courts have granted summary judgment for

defendants on such claims, concluding that PTO 861 is the

law of the case on that issue.

_________________________________________________________________

4. Zimmer, Inc., a manufacturer of the pedicle screw device, initially was

included as a defendant in the Intercompany/Association Conspiracy

claim brought by PLC. PLC and Zimmer have since settled their

respective claims against each other.

5. In addition, the omni complaints alleged that defendants conspired to

commit fraud by actively concealing material facts at the seminars. After

PTO 861 was entered, however, plaintiffs moved for voluntary dismissal

with prejudice of their conspiracy to defraud claims, which the District

Court granted. See In re Orthopedic Bone Screw Prods. Liability Litig.,

MDL 1014, Memorandum and Pretrial Order No. 1543, op. at 6 (E.D. Pa.

Aug. 13, 1998).

12

Also in PTO 861, the District Court denied defendants'

motion to dismiss all claims premised upon their speech at

the seminars. Defendants had argued that such speech is

protected by the First Amendment and therefore cannot be

the basis for imposing civil liability. The District Court

rejected this argument, holding that the complaints allege

false and misleading commercial speech, which does not

qualify for First Amendment protection. The court also

declined to dismiss plaintiffs' claims on the basis that they

failed to plead reliance and causation adequately, and it

denied the motions of several defendants -- the American

Academy of Orthopedic Surgeons, the Scoliosis Research

Society, and the North American Spine Society -- for

attorney's fees and sanctions under 28 U.S.C. S 1927, Fed.

R. Civ. P. 54(d), and the court's inherent powers.

Because there is complete diversity of all plaintiffs and

defendants, the District Court had jurisdiction over each

civil action under 28 U.S.C. S 1332. In In re Orthopedic

Bone Screw Prods. Liability Litig., MDL 1014, Memorandum

and Pretrial Order No. 1543, (E.D. Pa. Aug. 13, 1998), the

District Court issued certification for final judgment under

Fed. R. Civ. P. 54(b) on all of plaintiffs' conspiracy and

concert of action allegations and complaints encompassed

in MDL No. 1014. Therefore, we have jurisdiction under 28

U.S.C. S 1291.

II. ANALYSIS

A. Dismissal of the Conspiracy and Concert of Action

Claims

We first address the dismissal of plaintiffs' conspiracy

and concert of action claims. This ruling was premised

upon the District Court's determination that civil

conspiracy does not provide a right of action in the absence

of an underlying tort; rather, it "renders each conspirator

vicariously liable for the commission of an act that is

independently actionable under state law and is in

furtherance of the conspiracy." PTO 861, at 23. Therefore,

the court held that plaintiffs' claims failed to state a cause

of action upon which relief could be granted. See id. at 25.

We exercise plenary review of this conclusion. See

13

Steamfitters Local Union No. 420 v. Phillip Morris, Inc., 171

F.3d 912, 919 (3d Cir. 1999).

No federal court of appeals has addressed the legal

cognizability of a claim for conspiracy to violate the FDCA.6

It is well settled, however, that the FDCA creates no private

right of action. See 21 U.S.C. S 337(a) (restricting FDCA

enforcement to suits by the United States); In re Orthopedic

Bone Screw Prods. Liability Litig., 159 F.3d 817, 824 (3d

Cir. 1998) ("It is . . . well established that Congress has not

created an express or implied private cause of action for

violations of the FDCA or the MDA."); PDK Labs., Inc. v.

Friedlander, 103 F.3d 1105, 1113 (2d Cir. 1997) (holding

that plaintiff 's suit "represents an impermissible attempt to

enforce the FDCA through a private right of action"); Mylan

Labs., Inc. v. Matkari, 7 F.3d 1130, 1139 (4th Cir. 1993)

(same). The question, then, is whether violation of a federal

statute imposing criminal penalties but establishing no

private right of action may serve as a basis for civil recovery

under state conspiracy law.

The established rule is that a cause of action for civil

conspiracy requires a separate underlying tort as a

predicate for liability. Thus, one cannot sue a group of

defendants for conspiring to engage in conduct that would

not be actionable against an individual defendant. Instead,

" `actionable civil conspiracy must be based on an existing

_________________________________________________________________

6. In addition to the District Court here, one other federal district

court

has addressed the issue:

[A] conspiracy is only actionable if the acts in question, when

committed by a single person, would also be actionable. Defendant

. . . alleges that the acts complained of in count II are simply

violations of the FDCA, the act which comprehensively regulates the

marketing of prescription drugs in the United States, and that the

FDCA does not create a private right of action for enforcement by

private individuals such as plaintiffs.

To the extent that plaintiffs were attempting to assert a cause of

action under the FDCA, defendant would be correct.

Hawkins v. Upjohn Co., 890 F. Supp. 609, 611 (E.D. Tex. 1994) (applying

Texas law). The Hawkins court found that plaintiffs' complaint, though

poorly worded, actually alleged a conspiracy to commit fraud and

therefore was independently actionable under state law. See id.

14

independent wrong or tort that would constitute a valid

cause of action if committed by one actor.' " Posner v. Essex

Ins. Co., 178 F.3d 1209, 1218 (11th Cir. 1999) (quoting

Williams Elec. Co. v. Honeywell, Inc., 772 F. Supp. 1225,

1239 (N.D. Fla. 1991)) (applying Florida law); accord Applied

Equip. Corp. v. Litton Saudi Arabia Ltd., 869 P.2d 454, 457

(Cal. 1994) ("Standing alone, a conspiracy does no harm

and engenders no tort liability. It must be activated by the

commission of an actual tort."); Stoldt v. City of Toronto,

678 P.2d 153, 161 (Kan. 1984) ("Conspiracy is not

actionable without commission of some wrong giving rise to

a cause of action independent of the conspiracy."); Alleco,

Inc. v. Harry & Jeanette Weinberg Found., Inc., 665 A.2d

1038, 1045 (Md. 1995) ("No action in tort lies for conspiracy

to do something unless the acts actually done, if done by

one person, would constitute a tort.") (citation omitted);

Alexander & Alexander of N.Y., Inc. v. Fritzen, 503 N.E.2d

102, 102-03 (N.Y. 1986) ("[A] mere conspiracy to commit a

tort is never of itself a cause of action. Allegations of

conspiracy are permitted only to connect the actions of

separate defendants with an otherwise actionable tort.")

(citations omitted).

Because this multidistrict litigation implicates the state

law of many different jurisdictions, we have reviewed the

law of every applicable jurisdiction on this point. Having

done so, we are unaware of any jurisdiction that recognizes

civil conspiracy as a cause of action requiring no separate

tortious conduct. To the contrary, the law uniformly

requires that conspiracy claims be predicated upon an

underlying tort that would be independently actionable

against a single defendant.7 Because plaintiffs here could

_________________________________________________________________

7. See, e.g., Hanten v. School Dist. of Riverview Gardens, 183 F.3d 799,

809 (8th Cir. 1999) ("[A] claim of civil conspiracy `does not set forth an

independent cause of action but rather is sustainable only after an

underlying tort claim has been established . . . .' " (quoting K & S

Partnership v. Continental Bank, N.A., 952 F.2d 971, 980 (8th Cir. 1991))

(applying Missouri law); Gaming Corp. of America v. Dorsey & Whitney,

88 F.3d 536, 551 (8th Cir. 1996) ("[C]onspiracy is based on the

commission of an underlying tort.") (applying Minnesota law); Halberstam

v. Welch, 705 F.2d 472, 479 (D.C. Cir.1983) ("Since liability for civil

conspiracy depends on performance of some underlying tortious act, the

15

not sue an individual defendant for an alleged violation of

the FDCA, it follows that they cannot invoke the mantle of

conspiracy to pursue the same cause of action against a

group of defendants. A claim of civil conspiracy cannot rest

solely upon the violation of a federal statute for which there

is no corresponding private right of action.

_________________________________________________________________

conspiracy is not independently actionable; rather, it is a means for

establishing vicarious liability for the underlying tort.") (applying

District

of Columbia law); Cunningham v. PFL Life Ins. Co., 42 F. Supp.2d 872,

884 (N.D. Iowa 1999) ("[C]onspiracy does not state an independent cause

of action, but rather requires the commission of an underlying wrong for

which liability may be extended to an additional defendant by virtue of

a conspiracy.") (applying Iowa law); University Sys. of N.H. v. United

States Gypsum Co., 756 F. Supp. 640, 652 (D.N.H. 1991) ("For a civil

conspiracy to exist, there must be an underlying tort which the alleged

conspirators agreed to commit. Conspiracy, then, serves as a device

through which vicarious liability for the underlying tort may be imposed

on all who commonly plan, take part in, further by cooperation, lend aid

to, or encourage the wrongdoers' acts.") (applying New Hampshire law);

In re North Dakota Personal Injury Asbestos Litig. No. 1, 737 F. Supp.

1087, 1095 (D.N.D. 1990) ("One of the parties must commit some act in

pursuance of the agreement that is itself a tort for civil conspiracy to

exist.") (applying North Dakota law); McGlasson v. Barger, 431 P.2d 778,

780 (Colo. 1967) ("[U]nless a civil action in damages would lie against

one of the conspirators, if the act was done by him alone, it will not lie

against many acting in concert.") (quoting Pullen v. Headberg, 127 P.

954, 955 (Colo. 1912)); O'Neal v. Home Town Bank of Villa Rica, 514

S.E.2d 669, 675 (Ga. Ct. App. 1999) ("Absent the underlying tort, there

can be no liability for civil conspiracy."); Cohen v. Bowdoin, 288 A.2d

106

(Me. 1972) (" `[C]onspiracy' fails as the basis for the imposition of

civil

liability absent the actual commission of some independently recognized

tort; and when such separate tort has been committed, it is that tort,

and not the fact of combination, which is the foundation of the civil

liability."); Admiral Ins. Co. v. Columbia Casualty Ins. Co., 486 N.W.2d

351, 359 (Mich. Ct. App. 1992) ("Because [plaintiff] has failed to state

any tortious action, its conspiracy action must also fail."); Middlesex

Concrete Prods. & Excavating Corp. v. Carteret Indus. Ass'n, 181 A.2d

774, 779 (N.J. 1962) ("[A] conspiracy cannot be made the subject of a

civil action unless something has been done which, absent the

conspiracy, would give a right of action."); Nix v. Temple Univ., 596 A.2d

1132, 1137 (Pa. Super. Ct. 1991) (" `Absent a civil cause of action for a

particular act, there can be no cause of action for civil conspiracy.' ")

(quoting Pelagatti v. Cohen, 536 A.2d 1337, 1342 (Pa. Super. Ct. 1987)).

16

Plaintiffs contend the doctrine of per se liability (often

called "negligence per se") establishes that violations of

federal statutes can be the basis of common law tort liability.8

They cite the following passage from the Restatement of

Torts:

Even where a legislative enactment contains no express

provision that its violation shall result in tort liability,

and no implication to that effect, the court may, and in

certain types of cases customarily will, adopt the

requirements of the enactment as the standard of

conduct necessary to avoid liability for negligence. The

same is true of municipal ordinances and

administrative regulations.

Restatement (Second) of Torts S 285 cmt. c (1977). In

addition, plaintiffs rely on numerous cases in which courts,

in determining common law tort liability, have considered

whether the defendant's conduct violated federal law. See,

e.g., Stanton ex rel. Brooks v. Astra Pharmaceutical Prods.,

Inc., 718 F.2d 553, 565 (3d Cir. 1983) (holding that failure

to comply with FDA regulations constituted negligence per

se under Pennsylvania law); Orthopedic Equip. Co. v.

Eutsler, 276 F.2d 455, 461 (4th Cir. 1960) ("[W]e think that

a violation of the Federal Food, Drug, and Cosmetic Act is

negligence per se in Virginia . . . .").

In these and many other cases, courts have found that

violations of a federal statute or regulations constituted

negligence per se under state law. But the cases make clear

the doctrine of per se liability does not create an

independent basis of tort liability but rather establishes, by

reference to a statutory scheme, the standard of care

appropriate to the underlying tort. See, e.g. , Grove Fresh

Distribs., Inc. v. Flavor Fresh Foods, Inc., 720 F. Supp. 714,

716 (N.D. Ill. 1989) ("Grove Fresh relies on the FDA

regulation merely to establish the standard or duty which

defendants allegedly failed to meet. Nothing prohibits Grove

Fresh from using the FDCA or its accompanying

_________________________________________________________________

8. The phrase "per se liability" is used primarily in the antitrust

context,

in which horizontal price-fixing arrangements are held to violate the

Sherman Act regardless of their reasonableness. See FTC v. Superior Ct.

Trial Lawyers Ass'n, 493 U.S. 411, 435 (1990); United States v. Socony-

Vacuum Oil Co., 310 U.S. 150, 225-26 n.59 (1940).

17

regulations in that fashion."). Liability per se enables

plaintiffs to establish as a matter of law that the

defendant's conduct constituted a breach of duty in a

negligence action, so that only causation and damages need

be proved. See In re TMI, 67 F.3d 1103, 1118 (3d Cir. 1995)

("[W]here defendants violated the relevant statute or

regulation, courts have held as a matter of law that

plaintiffs have satisfied the first two elements of their cause

of action: the duty and breach of duty."); Stanton, 718 F.2d

at 564 n.22 (noting, in the FDCA context, that

"Pennsylvania law views a statutory violation as conclusive

evidence of negligence, in the absence of an excuse for that

violation . . . . We emphasize, however, that the

nomenclature `negligence per se' does not mean that a

plaintiff seeking to recover under that doctrine may

dispense with establishing proximate cause."). See generally

1 J.D. Lee & Barry A. Lindahl, Modern Tort Law: Liability

& Litigation S 3.33, at 102 (1980) ("Under the per se rule,

the violation of an applicable statute is conclusive proof of

negligence, leaving only the question of causation to be

determined.") (citation omitted).

The theory of per se liability advanced by the plaintiffs

here is quite different. Plaintiffs do not invoke the statutory

violations to prove defendants' liability for a separate

underlying tort, but instead contend the violations

themselves form a cause of action. This interpretation of

per se liability would allow private plaintiffs to recover for

violations of a federal statute that creates no private cause

of action and, in fact, expressly restricts its enforcement to

the federal government. See 21 U.S.C.A.S 337(a) (West

Supp. 1999).9 Plaintiffs' theory would undermine section

337(a) by establishing a private, state-law cause of action

for violations of the FDCA, so long as those actions are

brought against more than one defendant. We do not

believe the concept of per se liability supports such a

result.

Nor are we persuaded by plaintiffs' argument that

_________________________________________________________________

9. The statute also permits state governments to bring suit in certain

limited circumstances, but only upon approval by the Secretary of

Health and Human Services. See id. S 337(b).

18

Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) and In re

Orthopedic Bone Screw Prods. Liability Litig., 159 F.3d 817

(3d Cir. 1998) (Bone Screw I) dictate reversal of the District

Court. In Medtronic, the Supreme Court held the Medical

Device Amendments ("MDA") do not preempt state common

law negligence claims against manufacturers of defective

medical devices. The Court observed that interpretation of

a preemption provision does not occur in a "contextual

vacuum," 518 U.S. at 485, but must be informed by two

additional considerations: (1) the presumption against

preemption unless clearly and manifestly indicated by

Congress; and (2) the principle that "the purpose of

Congress is the ultimate touchstone" in determining the

extent of preemption. Id. Finding that Congress did not

intend the MDA to foreclose state-law negligence lawsuits,

the Court allowed plaintiffs' claims to proceed.

In Bone Screw I, we interpreted Medtronic to mean that

common law claims of fraudulent misrepresentation are not

preempted by the MDA, even if the conduct underlying

those claims violated the FDCA. See 159 F.3d at 825

(holding that Medtronic "overrules everything in [Michael v.

Shiley, Inc., 46 F.3d 1316 (3d Cir. 1995)] that would

prevent a plaintiff from pursuing a cause of action for

fraudulent misrepresentation based on common law

principles"). Notably, we reserved judgment on whether the

plaintiffs had stated a claim under state law upon which

relief could be granted. See id. at 829.

Although plaintiffs concede the District Court here"did

not explicitly invoke preemption principles," they claim that

"its decision was plainly based on a construction of

legislative intent." (Appellants' Br. at 31 n.21.) They argue

Medtronic and Bone Screw I stand for the proposition that

Congress did not intend to foreclose state law remedies

based on violations of federal medical device law, and the

District Court therefore erred in dismissing claims based on

conspiracy to violate the FDCA. Medtronic and Bone Screw

I are crucially different from this case, however. Both raised

the issue whether state common law claims were

preempted by the FDCA and Medical Device Amendments.

After Medtronic, it is clear that such claims survive, and

Bone Screw I so held. Consequently, state law claims such

19

as negligence, breach of implied warranty, and fraudulent

misrepresentation are viable, even to the extent they seek

recovery for conduct that may also have violated the FDCA.

But neither Medtronic nor Bone Screw I purports to allow

private plaintiffs to sue directly for violations of a federal

statute in the absence of a separate underlying cause of

action. They merely hold that such causes of action as

previously existed under state law were not preempted by

the FDCA and Medical Device Amendments.

We will therefore uphold the District Court's dismissal of

the conspiracy and concert of action claims alleging a

conspiracy to violate the FDCA.

B. First Amendment Protection

The District Court also denied defendants' motions to

dismiss the conspiracy and concert of action claims on

First Amendment grounds. These claims are based largely

upon the allegation that defendants conspired to commit

fraud by actively concealing material facts at the seminars.

Allegedly, speakers at the seminars failed to disclose that

they had a direct financial stake in the use of the devices,

that the devices had not yet been approved by the FDA, and

that testing had raised concerns about their safety.

According to defendants, imposition of liability for their

speech at the seminars would violate their First

Amendment rights.

The First Amendment's prohibition on abridging the

freedom of speech applies to the states through the Due

Process Clause of the Fourteenth Amendment. See Duncan

v. Louisiana, 391 U.S. 145, 148 (1968). Imposition of civil

liability, such as the award of money damages, is treated

no less stringently than direct regulation on speech: "The

fear of damage awards . . . may be markedly more

inhibiting than the fear of prosecution under a criminal

statute." New York Times Co. v. Sullivan, 376 U.S. 254,

279-280 (1964); see also Cohen v. Cowles Media Co., 501

U.S. 663, 676 n.4 (1991) (Blackmun, J., dissenting) ("[W]e

have long held that the imposition of civil liability based on

protected expression constitutes `punishment' of speech for

First Amendment purposes.").

20

The Supreme Court has long recognized a " `common-

sense distinction between speech proposing a commercial

transaction, which occurs in an area traditionally subject to

government regulation, and other varieties of speech.' "

Bolger v. Youngs Drug Prods. Corp., 463 U.S. 60, 65 (1983)

(quoting Ohralik v. Ohio State Bar Ass'n, 436 U.S. 447,

455-56 (1978)). Commercial speech is accorded a lesser

degree of First Amendment protection than other kinds of

speech. For instance, the government may enact content-

based restrictions on false or misleading commercial

messages. See, e.g., Central Hudson Gas & Elec. Corp. v.

Public Serv. Comm'n of N.Y., 447 U.S. 557, 562-63 (1980)

("[T]here can be no constitutional objection to the

suppression of commercial messages that do not accurately

inform the public about lawful activity. The government

may ban forms of communication more likely to deceive the

public than to inform it . . . ."); Virginia State Bd. of

Pharmacy v. Virginia Citizens Consumer Council, Inc., 425

U.S. 748, 771-72 n.24 (1976). In addition, "the First

Amendment does not protect commercial speech about

unlawful activities." 44 Liquormart, Inc. v. Rhode Island,

517 U.S. 484, 497 n.7 (1996); accord Pittsburgh Press Co.

v. Pittsburgh Comm'n on Human Relations, 413 U.S. 376

(1973) (same). Thus, an issue of primary significance here

is whether defendants' speech at the seminars was

commercial speech, and if so whether it was false and

misleading, or concerned unlawful activities.

Commercial speech is "broadly defined as expression

related to the economic interests of the speaker and its

audience, generally in the form of a commercial

advertisement for the sale of goods and services." U.S.

Healthcare, Inc. v. Blue Cross of Greater Phila., 898 F.2d

914, 933 (3d. Cir. 1990) (citing Bolger, 463 U.S. at 66-67;

Central Hudson, 447 U.S. at 561). In deciding whether

speech is commercial, we consider the following factors: "(1)

is the speech an advertisement; (2) does the speech refer to

a specific product or service; and (3) does the speaker have

an economic motivation for the speech. An affirmative

answer to all three questions provides `strong support' for

the conclusion that the speech is commercial." U.S.

Healthcare, 898 F.2d at 933 (citation omitted). At the same

time, we must be mindful of the "difficulty of drawing bright

21

lines that will clearly cabin commercial speech in a distinct

category." City of Cincinnati v. Discovery Network, Inc., 507

U.S. 410, 419 (1993). Often, speech consists of"complex

mixtures of commercial and noncommercial elements."

Bolger, 463 U.S. at 81 (Stevens, J., concurring). Where the

commercial and noncommercial elements of speech are

"inextricably intertwined," the court must apply the "test for

fully protected expression." Riley v. National Fed'n of the

Blind of N.C., Inc., 487 U.S. 781, 796 (1988).

At this stage in the proceedings, it is difficult to

determine precisely what portion of the seminars, if any,

consisted of a sales pitch to the attendees and what portion

was non-commercial medical discussion. The defendants

characterize the seminars as teaching events aimed at

promoting "continuing medical education" and accordingly

contend that the speech is entitled to the highest level of

First Amendment protection. Plaintiffs, on the other hand,

liken the seminars to medical "Tupperware parties" at

which defendants' sole objective was to generate sales of

their products.

We believe there is a sufficient factual dispute about the

nature of the seminars to preclude granting defendants'

motion to dismiss on First Amendment grounds. The

amended omni complaints allege, inter alia, that the

seminars were organized by sales representatives employed

by the participating manufacturers; that these

representatives invited spinal surgeons to attend and later

followed up with phone calls in an effort to generate sales;

that employees of the manufacturers staffed sales booths

and distributed videotapes, product catalogues, and other

literature at the seminars; and that the speakers at the

seminars were doctors and scientists who had entered into

lucrative royalty agreements giving them a direct financial

stake in the sales of bone screw devices. If true, these

allegations would provide strong support for characterizing

the seminars as commercial speech.

Defendants argue that even if their speech at the

seminars was commercial in nature (which they deny), it

constitutes "truthful, nonmisleading speech about a lawful

product" and therefore is protected. 44 Liquormart, 517

U.S. at 504; see also Greater New Orleans Broadcasting

22

Ass'n v. United States, ___ U.S. ___, 119 S. Ct. 1923 (1999)

(holding that a state may not ban nonmisleading

advertisements of legal gambling). Plaintiffs respond that

the speech at the seminars was highly misleading and

deceptive. The amended omni complaints allege defendants

knowingly withheld material facts at the seminars and

falsely represented to the physicians in attendance that the

devices were safe and effective for use in pedicle screw

fixation surgery.

Clearly, there is a considerable and unresolved factual

dispute regarding key elements of the speech at issue. In

order to dismiss the claims on First Amendment grounds,

we would have to determine either that defendants' speech

at the seminars was noncommercial in nature, or that it

was truthful or nonmisleading commercial speech

concerning a lawful product. In view of our obligation to

accept as true the factual allegations of the nonmoving

party, we are unwilling to do either at this point. Whether

the allegations in the omni complaints are true remains to

be determined. But dismissal is warranted only if"it

appears beyond doubt that the plaintiff can prove no set of

facts in support of his claim which would entitle him to

relief." Conley v. Gibson, 355 U.S. 41, 45-46 (1957). We do

not believe this standard has been met; therefore, we will

uphold the District Court's denial of defendants' motions to

dismiss. Of course, defendants are free to raise their First

Amendment argument in the transferor courts after the

factual record is more fully developed.

C. Plaintiffs' Theory of Damages

Defendants North American Spine Society, American

Academy of Orthopedic Surgeons, and Scoliosis Research

Society (collectively "the medical associations") submitted a

joint brief in which they argue that plaintiffs' claims should

be dismissed for failure to plead causation adequately. In

particular, they contend plaintiffs have not properly alleged

a causal connection between the seminars and the

decisions of individual physicians to use the bone screw

devices in surgery. They argue that in order to allege

proximate cause adequately, each plaintiff must

demonstrate that his or her surgeon relied upon

defendants' statements at the seminars in making the

23

decision to use the devices for pedicle fixation surgery, and

that this decision in turn caused the injury upon which

relief is sought. Plaintiffs' theory of causation, they claim,

eschews proof of individualized reliance in favor of an

unjustified extension of the "fraud-on-the-market-theory" of

liability developed in securities law. See Basic Inc. v.

Levinson, 485 U.S. 224 (1988).10 For their part, plaintiffs

claim their market theory of causation extended only to the

fraud aspect of their conspiracy claims, which they have

now discontinued, and they also dispute that they are

required to prove individualized causation. They argue it is

sufficient to show that the seminars contributed to the

creation of an unlawful black market for pedicle screw

fixation devices, in the absence of which plaintiffs would

not have been injured.

We believe these issues are best resolved under a plenary

standard in the transferor courts, rather than on the appeal

of a motion to dismiss. Whether plaintiffs have adequately

alleged causation depends greatly on the particulars of the

state law governing each claim. This fact alone counsels

against dismissing all claims on this basis. See Bone Screw

I, 159 F.3d at 826 ("While we are not in a position to

canvass all the potentially applicable law [of the transferor

jurisdictions], what we know about tort law generally

makes us unwilling to say that all of the plaintiffs' claims

will fail for want of the kind of a causation that will give rise

to liability."). There is no uniform rule governing the level of

specificity with which proximate cause must be proven in

the various jurisdictions involved in this litigation.

Moreover, many jurisdictions have adopted a "substantial

factor" test that does not lend itself to facile predictions

about which theories of damages will suffice. See, e.g.,

_________________________________________________________________

10. As noted, the medical associations previouslyfiled a petition for a

writ of mandamus invalidating plaintiffs' fraud-on-the-market theory as

a matter of law. In denying the writ, we observed that plaintiffs had

represented to the Court that they planned to assemble evidence of

individualized reliance through the discovery process, and that they

would rely on a fraud-on-the-market theory only in those cases where

reliance could not be proven. See In re Orthopedic Bone Screw Prods.

Liability Litig., MDL No. 1014, mem. op. at 8-9 (3d Cir. Nov. 10, 1997)

(unpublished opinion).

24

Parks v. AlliedSignal, Inc., 113 F.3d 1327, 1332 (3d Cir.

1997) ("When addressing causation, Pennsylvania has

rejected the `but for' test and adopted the `substantial

factor' test . . . ."); Dawson v. Bunker Hill Plaza Assocs.,

673 A.2d 847, 853 (N.J. Super Ct. App. Div. 1996)

("Liability attaches not only to the dominating cause but

also to any cause which constitutes at any event a

substantial factor in bringing about the injury.") (internal

quotation marks omitted); Abrahams v. Young & Rubicam,

Inc., 692 A.2d 709, 712 (Conn. 1997) ("[I]t is axiomatic that

proximate cause is an actual cause that is a substantial

factor in the resulting harm.") (internal quotation marks

omitted); State v. Hubka, 480 N.W.2d 867, 869 (Iowa 1992)

("The general rule is that a defendant's conduct is the

proximate cause of injury or death to another if (1) her

conduct is a `substantial factor' in bringing about the harm

and (2) there is no other rule of law relieving the defendant

of liability because of the manner in which her conduct

resulted in the harm.").

We believe the transferor courts are in the best position

to determine whether the applicable state law permits

plaintiffs to recover damages without proving individual

reliance. Accordingly, we decline to dismiss plaintiffs'

claims on this basis.

D. Costs and Sanctions

The medical associations filed cross-motions for costs

and sanctions under 28 U.S.C. S 1927, Fed. R. Civ. P.

54(d), and the court's inherent judicial powers. In support,

they argued that plaintiffs acted in bad faith and needlessly

multiplied the litigation by bringing the conspiracy to

defraud claim despite having no means of proving

individualized reliance. The District Court denied these

motions, finding that defendants had not demonstrated

"willful bad faith" on the part of the plaintiffs. See In re

Orthopedic Bone Screw Prods. Liability Litig., MDL 1014,

Memorandum and Pretrial Order No. 1543, op. at 8-9 (E.D.

Pa. Aug. 13, 1998) ("PTO 1543").

We review the denial of attorney's fees and costs for

abuse of discretion. See Gioioso v. Stuebben, 979 F.2d 956,

959 (3d Cir. 1992). Such an abuse occurs when the court's

25

decision " `rests upon a clearly erroneousfinding of fact, an

errant conclusion of law or an improper application of law

to fact.' " Morgan v. Perry, 142 F.3d 670, 682 (3d Cir. 1998)

(quoting Hanover Potato Prods., Inc. v. Shalala, 989 F.2d

123, 127 (3d Cir. 1993)).

Imposition of attorney's fees and costs under section

1927 is reserved for behavior " `of an egregious nature,

stamped by bad faith that is violative of recognized

standards in the conduct of litigation.' " Baker Indus., Inc.

v. Cerberus Ltd., 764 F.2d 204, 208 (3d Cir. 1985) (quoting

Colucci v. New York Times Co., 533 F. Supp. 1011, 1014

(S.D.N.Y. 1982)). Thus, fees may not be awarded unless

there is "a finding of willful bad faith on the part of the

offending attorney." Baker, 764 F.2d at 209. An award of

fees under the court's inherent powers requires a similar

finding. See Chambers v. NASCO, Inc., 501 U.S. 32, 45-46

(1991) (court may assess fees under inherent powers when

a party has acted " `in bad faith, vexatiously, wantonly, or

for oppressive reasons' ") (quoting Alyeska Pipeline Serv. Co.

v. Wilderness Soc'y, 421 U.S. 240, 258-59 (1975)).

We agree with the District Court that no finding of bad

faith was warranted here. As noted, several of plaintiffs'

claims were premised upon a theory of damages that

defendants characterize as a "fraud-on-the-market" theory.

They contend this theory is so lacking in merit that it

should never have been advanced, and that plaintiffs'

reliance on it needlessly multiplied the proceedings and

incurred wasteful expense. Regardless of whether plaintiffs'

theory of causation is ultimately accepted by transferor

courts, we cannot say the plaintiffs acted in bad faith in

raising it. The Supreme Court has specifically instructed

that courts should be wary of chilling legitimate advocacy

by imposing fees too hastily: "[I]t is important that a district

court resist the understandable temptation to engage in

post hoc reasoning by concluding that, because a plaintiff

did not prevail, his action must have been unreasonable or

without foundation. This kind of hindsight logic could

discourage all but the most airtight claims . . . ."

Christiansburg Garment Co. v. EEOC, 434 U.S. 412, 421-22

(1978); accord Baker, 764 F.2d at 208 (bad-faith

requirement is "necessary to avoid chilling an attorney's

26

legitimate obligation to represent his client zealously").

Restraint is particularly important where, as here, the case

presents complex factual and legal issues. See In re

Kunstler, 914 F.2d 505, 523 (4th Cir. 1990) (sanctioning

powers should be exercised with restraint to avoid chilling

"novel factual or legal theories"); Barney v. Holzer Clinic,

Ltd., 110 F.3d 1207, 1213 (6th Cir. 1997) (holding that an

award of fees under section 1927 was not warranted where

the "central issue was one of first impression"); United

States v. Alexander, 981 F.2d 250, 253 (5th Cir. 1993)

(vacating an assessment of sanctions because of"the

absence of authority in this Circuit combined with the

complexity of the issue").

Additionally, we believe the history of this litigation

undermines any claim that plaintiffs acted in "actual" or

"willful" bad faith, as required for an award of fees under

section 1927. Baker, 764 F.2d at 208-09. Early in

consolidated pretrial proceedings, the District Court raised

the issue whether the original omni complaints satisfied the

requirements of Fed. R. Civ. P. 11, which provides for the

imposition of sanctions upon attorneys who submit

complaints lacking a sufficient legal and factual basis. In

response, plaintiffs submitted a 750-page Particularized

Statement of Facts accompanied by numerous exhibits,

explicating in more detail their claims for relief. The District

Court then determined that the complaints did not violate

Rule 11 but still were not pleaded with sufficient

particularity, and granted plaintiffs' leave to replead. See In

re Orthopedic Bone Screw Prods. Liability Litig., MDL No.

1014, Pretrial Order No. 477 (E.D. Pa. Aug. 22, 1996). In

response, the PLC developed amended "form" complaints

that were expressly authorized by the District Court before

being transmitted to the various plaintiffs' attorneys, who

modified them as necessary to suit the particulars of their

clients' cases. Although this history is not dispositive, we

believe it strongly supports the District Court's

determination that plaintiffs' counsel did not act in bad

faith; to the contrary, they responded to the court's request

to cure potential defects in the complaints before

proceeding further.

Finally, we also note that defendants' principal argument

for imposing costs -- namely, that plaintiffs cannot prove

27

that defendants' conduct at the seminars was the

proximate cause of their injuries -- is largely a question of

fact which remains unresolved. Plaintiffs still contend that

individual reliance can be proven in many cases, and we

will not second-guess this representation on the appeal of

a motion for attorney's fees. As the District Court aptly

observed, "If this court imposed sanctions for prosecuting

these claims the court would implicitly engage in fact

finding that is typically reserved for a jury." PTO 1543, at

10. We therefore see no abuse of discretion in the court's

denial of the medical associations' motion for attorney's fees

and costs.

III. CONCLUSION

We hold that the District Court properly dismissed

plaintiffs' conspiracy and concert of action claims based on

violations of the FDCA, because these claims failed to state

a claim upon which relief can be granted. We alsofind no

error in the District Court's denial of defendants' motions to

dismiss. At this stage in the proceedings, it would be

premature to conclude that even if plaintiffs' allegations are

true, defendants' speech at the seminars could not possibly

form the basis of civil liability under the First Amendment.

Similarly, we do not believe plaintiffs' theory of damages is

so devoid of legal support in all jurisdictions that it can be

dismissed outright in consolidated pretrial proceedings.

Defendants, of course, are free to challenge its legal viability

in the transferor courts. We will also uphold the denial of

the medical associations' motions for attorney's fees and

costs.

Accordingly, we will affirm the judgment of the District

Court.

A True Copy:

Teste:

Clerk of the United States Court of Appeals

for the Third Circuit

28

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.